The authors showed further that in human subjects with obesity, A2B receptor expression correlated strongly with expression of the insulin receptor substrate 2, and suggested that A2B receptor agonists have potential for the treatment of type 2 diabetes and obesity. This evidence concerns the gene IRS2 and obesity due to melanocortin 4 receptor deficiency.